Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ISOLYTE S IN DEXTROSE 5% IN PLASTIC CONTAINER vs ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Isolyte S in Dextrose 5% is a combination of electrolytes and dextrose. Dextrose provides caloric support and helps correct hypoglycemia. Electrolytes (sodium, potassium, magnesium, chloride, acetate, gluconate) replenish fluid and electrolyte deficits, maintaining osmotic balance and acid-base homeostasis.
Isolyte E in Dextrose 5% provides fluid, electrolytes, and calories. Dextrose is metabolized to carbon dioxide and water, yielding energy. Electrolytes (sodium, potassium, magnesium, chloride, acetate, gluconate) maintain acid-base balance and osmotic pressure.
Intravenous replacement of fluid and electrolyte losses,Maintenance fluid therapy,Correction of metabolic acidosis (due to acetate and gluconate precursors of bicarbonate)
FDA-approved: For intravenous administration as a source of water, electrolytes, and calories in patients requiring fluid and electrolyte replacement.,Off-label: Not typically used off-label; primarily for maintenance or replacement therapy.
Intravenous infusion; rate and volume determined by clinical condition, fluid and electrolyte requirements. Typical adult dose: 500-1000 m L as a single infusion, administered at a rate not exceeding 50 m L/kg/day.
Intravenous infusion; typical adult dose is 1000-2000 m L per day (30 m L/kg/day) adjusted for fluid and electrolyte needs; rate based on clinical status.
Not applicable as a fixed pharmacokinetic parameter; dextrose half-life ~10 minutes (rapidly metabolized); electrolytes distribute and are cleared according to renal function. In patients with normal renal function, elimination half-life of water and electrolytes varies with hydration status and GFR.
Not applicable; components are endogenous substances. Dextrose half-life ~15-20 min after infusion; electrolytes distribute and are cleared renally with half-lives dependent on renal function.
Dextrose is metabolized to carbon dioxide and water via glycolysis and the citric acid cycle, releasing energy. Electrolytes are not metabolized; they are excreted renally or utilized in physiological processes.
Dextrose undergoes glycolysis and the citric acid cycle; electrolytes are not metabolized but are excreted or incorporated into body pools.
Renal elimination of water and electrolytes; dextrose is metabolized to CO2 and water, with <1% excreted unchanged in urine. Sodium and potassium are primarily excreted renally; acetate is metabolized to bicarbonate and excreted via lungs as CO2.
ISOLYTE E in Dextrose 5% is a balanced electrolyte solution with glucose. Electrolytes are primarily excreted renally; water and dextrose are metabolized. Biliary/fecal excretion is negligible. Dextrose is metabolized to CO2 and water.
None for dextrose, sodium, potassium, chloride; acetate minimally bound (<10% to albumin).
None for electrolytes and dextrose; sodium, potassium, chloride, magnesium, acetate, and gluconate are free ions in solution.
Dextrose: ~0.2 L/kg (total body water); sodium: ~0.6 L/kg (extracellular fluid); potassium: ~0.6 L/kg (total body water but primarily intracellular). Vd corresponds to total body water for electrolyte components.
Sodium and chloride distribute primarily in extracellular fluid (~0.2 L/kg). Dextrose distributes in total body water (~0.6 L/kg). Potassium distributes in intracellular fluid (~0.6 L/kg after equilibration).
100% bioavailability via intravenous route.
100% intravenous; not administered by other routes.
Contraindicated in patients with anuria or severe renal impairment (e GFR < 30 m L/min/1.73 m²). For mild to moderate impairment (e GFR 30-89 m L/min/1.73 m²), monitor serum potassium and renal function; adjust infusion rate based on fluid and electrolyte status.
In renal impairment (e GFR < 30 m L/min/1.73m²), reduce total volume to 500-1000 m L/day with careful monitoring of potassium, sodium, and glucose; avoid if hyperkalemia or fluid overload.
No specific Child-Pugh based dose adjustment required. Use with caution in patients with severe hepatic impairment due to risk of fluid overload and electrolyte imbalances; monitor serum sodium and potassium.
No specific dose adjustment for Child-Pugh class; monitor for fluid overload and electrolyte imbalances; in severe hepatic impairment, reduce volume to 500-1000 m L/day.
Intravenous infusion; dose based on weight and clinical condition. Typical rate: 5-20 m L/kg as a single dose, not to exceed 50 m L/kg/day. Adjust based on serum electrolyte levels and fluid balance.
Weight-based: 20-50 m L/kg/day for maintenance; neonates and infants: 100-150 m L/kg/day; adjust based on glucose, electrolytes, and hydration status; maximum rate 4 m L/kg/hour for neonates.
Use with caution due to increased risk of fluid overload, renal impairment, and electrolyte disturbances. Initiate at lower infusion rates and monitor renal function, serum electrolytes, and volume status closely.
Start with lower volumes (500-1000 m L/day) due to decreased renal function and risk of fluid overload; monitor serum electrolytes, glucose, and central venous pressure.
None.
Not applicable; no FDA boxed warning exists for this product.
Avoid in patients with hyperglycemia, severe renal impairment, or anuria,Monitor serum electrolytes and glucose levels during administration,Use with caution in patients with heart failure, renal disease, or those receiving corticosteroids,Risk of fluid overload and electrolyte imbalances,Do not administer unless solution is clear and container is intact
Monitor serum electrolytes, fluid balance, and glucose levels; avoid fluid overload in patients with cardiac or renal impairment; risk of hyperglycemia in diabetic patients; use with caution in patients with metabolic alkalosis or hypokalemia.
Hyperglycemia,Severe renal impairment (anuria or oliguria),Hypersensitivity to any component,Patients with elevated lactate levels or lactic acidosis
Hypersensitivity to any component; clinically significant hyperglycemia; severe metabolic acidosis; hyperkalemia (for potassium-containing formulations); hypermagnesemia; fluid overload conditions.
No direct food interactions; however, dextrose content may affect blood glucose. Patients on a glucose-restricted diet should be monitored. No specific dietary restrictions required during administration.
No specific food interactions known. Monitor electrolyte intake in patients with electrolyte imbalances.
ISOLYTE S IN DEXTROSE 5% is an electrolyte and carbohydrate solution. No specific teratogenic effects are associated with the components at therapeutic doses. However, during pregnancy, hyperglycemia or electrolyte imbalances may harm the fetus. First trimester: No known structural teratogenicity; second and third trimesters: Potential for fetal hyperglycemia, hyperinsulinemia, and electrolyte disturbances if maternal levels are not controlled. Use only if clearly needed.
ISOLYTE E in Dextrose 5% is an intravenous electrolyte and carbohydrate solution. There are no adequate and well-controlled studies in pregnant women. Animal reproduction studies have not been conducted. Dextrose and electrolytes are considered essential nutrients and are generally safe when used as indicated. However, administration during labor and delivery may cause fluid and electrolyte imbalances. First trimester risks are theoretical; second and third trimesters may involve risks of maternal hyperglycemia and fetal hyperinsulinemia if dextrose infusion is excessive. No specific teratogenicity reported.
ISOLYTE S IN DEXTROSE 5% components are endogenous and excreted into breast milk in varying amounts. Dextrose is normal milk sugar; electrolytes are present in milk. No adverse effects on nursing infants are expected at therapeutic doses. M/P ratio: Not established for the combination; individual electrolytes and dextrose have high milk/plasma ratios but are physiologic. Use with caution.
Dextrose and electrolytes are normal constituents of human milk. Following intravenous administration, concentrations in milk are expected to parallel maternal plasma levels. No specific M/P ratio is available. Use during breastfeeding is considered compatible; however, monitor for adverse effects in the infant such as electrolyte imbalance or hyperglycemia if maternal infusion is prolonged or high volume.
No specific dose adjustments required for pregnancy per se. However, increased plasma volume in pregnancy may alter distribution; monitor response and adjust rate based on clinical status, fluid balance, and laboratory values.
Pregnancy induces increased plasma volume and glomerular filtration rate, potentially diluting electrolytes and altering glucose metabolism. Dose adjustments may be required: consider lower dextrose infusion rates to avoid maternal hyperglycemia and fetal hyperinsulinemia. Monitor electrolytes closely; adjust potassium and magnesium supplementation as needed. No specific dose adjustment is universally recommended; individualize based on maternal weight, clinical status, and monitoring results.
ISOLYTE S in 5% Dextrose is a balanced electrolyte solution with 5% dextrose for maintenance fluid therapy. Monitor serum glucose closely, especially in diabetic patients. The solution provides potassium, magnesium, and phosphate; avoid in severe hyperkalemia, hypermagnesemia, or hyperphosphatemia. Contains acetate as a bicarbonate precursor; use with caution in patients with metabolic alkalosis. Do not administer with blood products due to risk of hemolysis. Incompatible with many drugs; confirm compatibility prior to Y-site administration.
ISOLYTE E in DEXTROSE 5% is an isotonic crystalloid solution for IV administration. Contains electrolytes (Na, K, Mg, Cl, acetate, gluconate) and dextrose 5%. Use with caution in patients with renal impairment, heart failure, or hyperkalemia. Monitor serum electrolytes, blood glucose, and fluid balance. Not for use as a sole source of nutrition. Do not administer if solution is discolored or contains particulates.
This fluid contains sugar (dextrose) and electrolytes to maintain your body's balance.,Tell your healthcare provider if you have diabetes, as this may affect your blood sugar.,Report any signs of allergic reaction: rash, itching, swelling, or difficulty breathing.,Notify your nurse if you experience pain, redness, or swelling at the IV site.,This solution is provided in a plastic container; do not remove from the overwrap until ready to use.
Inform your healthcare provider about all medical conditions, especially kidney disease, heart failure, or diabetes.,Report any signs of allergic reaction such as rash, itching, or trouble breathing.,Tell your doctor if you experience swelling, shortness of breath, or irregular heartbeat.,This solution contains dextrose (sugar); monitor blood glucose if you have diabetes.,Do not use if the bag is damaged or solution is cloudy.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ISOLYTE S IN DEXTROSE 5% IN PLASTIC CONTAINER vs ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER, answered by our medical review team.
ISOLYTE S IN DEXTROSE 5% IN PLASTIC CONTAINER is a Intravenous Electrolyte Solution that works by Isolyte S in Dextrose 5% is a combination of electrolytes and dextrose. Dextrose provides caloric support and helps correct hypoglycemia. Electrolytes (sodium, potassium, magnesium, chloride, acetate, gluconate) replenish fluid and electrolyte deficits, maintaining osmotic balance and acid-base homeostasis.. ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER is a Intravenous Electrolyte Solution with Dextrose that works by Isolyte E in Dextrose 5% provides fluid, electrolytes, and calories. Dextrose is metabolized to carbon dioxide and water, yielding energy. Electrolytes (sodium, potassium, magnesium, chloride, acetate, gluconate) maintain acid-base balance and osmotic pressure.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ISOLYTE S IN DEXTROSE 5% IN PLASTIC CONTAINER and ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ISOLYTE S IN DEXTROSE 5% IN PLASTIC CONTAINER is: Intravenous infusion; rate and volume determined by clinical condition, fluid and electrolyte requirements. Typical adult dose: 500-1000 m L as a single infusion, administered at a rate not exceeding 50 m L/kg/day.. The standard adult dose of ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER is: Intravenous infusion; typical adult dose is 1000-2000 m L per day (30 m L/kg/day) adjusted for fluid and electrolyte needs; rate based on clinical status.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ISOLYTE S IN DEXTROSE 5% IN PLASTIC CONTAINER and ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ISOLYTE S IN DEXTROSE 5% IN PLASTIC CONTAINER is classified as Category C. ISOLYTE S IN DEXTROSE 5% is an electrolyte and carbohydrate solution. No specific teratogenic effects are associated with the components at therapeutic doses. However, during pregn. ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER is classified as Category C. ISOLYTE E in Dextrose 5% is an intravenous electrolyte and carbohydrate solution. There are no adequate and well-controlled studies in pregnant women. Animal reproduction studies h. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.